Cargando…

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

BACKGROUND: The quantification of brain atrophy in relapsing-remitting multiple sclerosis (RRMS) may serve as a marker of disease progression and treatment response. We compared the association between first-line (FL) or second-line (SL) disease-modifying drugs (DMDs) and brain volume changes over t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Branger, Pierre, Parienti, Jean-Jacques, Sormani, Maria Pia, Defer, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794160/ https://www.ncbi.nlm.nih.gov/pubmed/26983008 http://dx.doi.org/10.1371/journal.pone.0149685

Ejemplares similares

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2023)

Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial
por: Defer, Gilles, et al.
Publicado: (2018)

Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients
por: Calocer, Floriane, et al.
Publicado: (2018)

Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis
por: Meijboom, Rozanna, et al.
Publicado: (2023)

The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Tsivgoulis, Georgios, et al.
Publicado: (2015)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
por: Alkhawajah, Mona, et al.
Publicado: (2011)

Regional gray matter atrophy and neuropsychologcal problems in relapsing-remitting multiple sclerosis
por: Lin, Aiyu, et al.
Publicado: (2013)

Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis
por: Jonkman, Laura E., et al.
Publicado: (2015)

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
por: Imani, Ali, et al.
Publicado: (2012)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Resting State Brain Entropy Alterations in Relapsing Remitting Multiple Sclerosis
por: Zhou, Fuqing, et al.
Publicado: (2016)

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
por: Goldberg, Lawrence, et al.
Publicado: (2009)

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
por: Cortese, Rosa, et al.
Publicado: (2022)

Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data
por: Datta, Sushmita, et al.
Publicado: (2015)

Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers
por: Bussas, Matthias, et al.
Publicado: (2021)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
por: Kizlaitienandedot, Rasa, et al.
Publicado: (2017)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension Study
por: Rinaldi, Francesca, et al.
Publicado: (2015)

Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Abdel-mannan, Omar A., et al.
Publicado: (2021)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis
por: Becker III, Russell V., et al.
Publicado: (2011)

The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis
por: Lie, Ingrid Anne, et al.
Publicado: (2022)

The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
por: Biolato, Marco, et al.
Publicado: (2021)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Decrease of Mutual Information in Brain Electrical Activity of Patients with Relapsing-Remitting Multiple Sclerosis
por: Lenne, Bruno, et al.
Publicado: (2013)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Defective structural RNA processing in relapsing-remitting multiple sclerosis
por: Spurlock, Charles F, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j6bc69iqb7dp6k86i0atfa69ng